Oral cyclophosphamide and etoposide in treatment of malignant pleural mesothelioma.
BACKGROUND
Malignant mesothelioma (MM) is almost always fatal and few treatment options are available. The aim of this study was to evaluate the efficacy of oral cyclophosphamide and etoposide for patients who underwent standard treatment for advanced MM.


METHODS
This study included 22 malignant pleural mesothelioma patients who were treated with oral cyclophosphamide and etoposide (EE).


RESULTS
The average follow-up period of the patients was 39.1 months. Under the treatment of oral EE, median progression- free survival was 7.7 months [95%CI HR (4.3-11.1)] and median overall survival was 28.1 months [95%CI HR (5.8-50.3)]. The treatment response rates were as follows: 4 patients (27.3%) had a partial response (PR), 12 (54.5%) had stable disease (SD), and progressive disease (PD) was observed in 6 (35.9%).


CONCLUSIONS
Oral EE can be administered effectively to patients with inoperable malignant mesothelioma who had previously received standard treatments.
Department of Medical Oncology, Antalya Education and Research Hospital, Antalya, Turkey E-mail : drsgunduz@gmail.com.
Seyda
S
Gunduz
Hasan
H
Mutlu
Sema Sezgin
SS
Goksu
Deniz
D
Arslan
Ali Murat
AM
Tatli
Mukremin
M
Uysal
Hasan Senol
HS
Coskun
Hakan
H
Bozcuk
Mustafa
M
Ozdogan
Burhan
B
Savas
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D005047:Etoposide / Q000008:administration & dosage; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008654:Mesothelioma / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D000086002:Mesothelioma, Malignant; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009367:Neoplasm Staging; D010997:Pleural Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D011379:Prognosis; D012189:Retrospective Studies; D015996:Survival Rate; D055815:Young Adult
D005047:Etoposide; D003520:Cyclophosphamide